Marica Meroni

List of Publications by Year
in descending order

51 papers	3,122 citations	218592 26 h-index	214721 47 g-index
58 all docs	58 docs citations	58 times ranked	3918 citing authors

#	Article	IF	Citations
1	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	0.6	506
2	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ˜†. Journal of Hepatology, 2020, 73, 505-515.	1.8	279
3	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	1.6	193
4	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology, 2021, 74, 775-782.	1.8	193
5	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Science Translational Medicine, 2018, 10, .	5.8	151
6	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 406-421.e7.	7.2	141
7	Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine, 2016, 48, 384-391.	1.5	119
8	Alcohol or Gut Microbiota: Who Is the Guilty?. International Journal of Molecular Sciences, 2019, 20, 4568.	1.8	106
9	miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. International Journal of Molecular Sciences, 2018, 19, 3966.	1.8	98
10	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	3.6	93
11	PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Human Molecular Genetics, 2016, 25, ddw341.	1.4	86
12	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	1.6	85
13	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients, 2019, 11, 2642.	1.7	81
14	Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. International Journal of Molecular Sciences, 2018, 19, 3857.	1.8	75
15	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut, 2020, 69, 1855-1866.	6.1	75
16	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine, 2020, 52, 102658.	2.7	71
17	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clinical Science, 2017, 131, 1301-1315.	1.8	64
18	Nutrition and Genetics in NAFLD: The Perfect Binomium. International Journal of Molecular Sciences, 2020, 21, 2986.	1.8	60

#	Article	IF	Citations
19	Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?. Metabolism: Clinical and Experimental, 2021, 117, 154708.	1.5	59
20	Î²-Klotho gene variation is associated with liver damage in children with NAFLD. Journal of Hepatology, 2020, 72, 411-419.	1.8	48
21	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development â€“ a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 229-242.	1.4	44
22	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	2.3	44
23	Fibronectin Type III Domainâ€“Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2660-2669.	1.8	42
24	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	2.0	42
25	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 666-675.	2.0	38
26	MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine, 2020, 57, 102866.	2.7	38
27	Genetics Is of the Essence to Face NAFLD. Biomedicines, 2021, 9, 1359.	1.4	30
28	mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients, 2019, 11, 2597.	1.7	24
29	MAFLD in COVID-19 patients: an insidious enemy. Expert Review of Gastroenterology and Hepatology, 2020, 14, 867-872.	1.4	23
30	Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. International Journal of Molecular Sciences, 2021, 22, 4173.	1.8	23
31	Notch signaling and progenitor/ductular reaction in steatohepatitis. PLoS ONE, 2017, 12, e0187384.	1.1	18
32	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 535-549.	2.0	18
33	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. Cancers, 2021, 13, 1783.	1.7	16
34	Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies. Biomedicines, 2022, 10, 182.	1.4	15
35	NDP-MSH treatment recovers marginal lungs during ex vivo lung perfusion (EVLP). Peptides, 2021, 141, 170552.	1.2	12
36	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine, 2021, 65, 103249.	2.7	11

#	Article	IF	Citations
37	Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Science Translational Medicine, 2022, 14, eabh3831.	5.8	11
38	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158765.	1.2	10
39	Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines, 2021, 9, 1524.	1.4	10
40	PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. International Journal of Molecular Sciences, 2022, 23, 2707.	1.8	9
41	MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. Journal of Internal Medicine, 2022, 291, 374-376.	2.7	8
42	Impact of natural neuromedinâ€B receptor variants on iron metabolism. American Journal of Hematology, 2020, 95, 167-177.	2.0	7
43	From Environment to Genome and Back: A Lesson from HFE Mutations. International Journal of Molecular Sciences, 2020, 21, 3505.	1.8	7
44	Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution. Biomedicines, 2022, 10, 648.	1.4	7
45	Î±-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study. Diagnostics, 2021, 11, 1628.	1.3	5
46	Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine, 2020, 1, 218-243.	1.5	4
47	PS-005-Evaluation of neuromedin-B receptor variants effect on iron metabolism and liver disease. Journal of Hepatology, 2019, 70, e7-e8.	1.8	0
48	PS-006-MBOAT7 downregulation induces hepatic lipid accumulation. Journal of Hepatology, 2019, 70, e8.	1.8	0
49	THU-323-Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. Journal of Hepatology, 2019, 70, e302.	1.8	0
50	FRI-320-TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion. Journal of Hepatology, 2019, 70, e536-e537.	1.8	0
51	FRI-333-ATG7 genetic variant and defective autophagy: A novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus. Journal of Hepatology, 2019, 70, e542.	1.8	0